Welcome to our dedicated page for ZyVersa Therapeutics SEC filings (Ticker: ZVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ZyVersa Therapeutics filings document the public-company record for a clinical-stage biopharmaceutical issuer whose common stock is quoted on the OTCQB Venture Market under ZVSA. Recent reports cover material agreements, securities purchase arrangements, convertible promissory notes, common stock purchase warrants and other capital-structure disclosures tied to company financing.
The filing record also includes Form 8-K disclosures for financial results, officer and director departures, Nasdaq delisting notices and Form 25 removal from listing and registration. Periodic-report notices and related exhibits document reporting status, governance matters and the company’s formal disclosure obligations.
ZyVersa Therapeutics (NASDAQ:ZVSA) has entered into a significant Equity Purchase Agreement with Williamsburg Venture Holdings. The agreement provides ZyVersa with the right to sell up to $10 million of common stock through June 24, 2027. The purchase price will be set at 94% of the lowest traded Volume-Weighted Average Price during a 3-day period after share issuance.
Key terms include a 2.5% commitment fee in additional shares, issuance limitations of 19.99% of outstanding shares without stockholder approval, and mandatory registration of shares within 120 days. The company will maintain control over the timing and amount of any sales based on market conditions and financing needs.